Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant (Q24655036)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant	scientific article

Statements

scholarly article

0 references

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant (English)

0 references

adaptive radiation therapy

0 references

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Jeffrey Schlom

0 references

James L. Gulley

10

object named as

James L Gulley

0 references

Seth M Steinberg

4

object named as

Seth M Steinberg

0 references

9

object named as

William L Dahut

0 references

author name string

Robert J Lechleider

1

0 references

Philip M Arlen

2

0 references

Kwong-Yok Tsang

3

0 references

Junko Yokokawa

5

0 references

Vittore Cereda

6

0 references

Kevin Camphausen

7

0 references

language of work or name

0 references

publication date

15 August 2008

0 references

Clinical Cancer Research

0 references

14

0 references

16

0 references

5284-91

0 references

Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

7 April 2017

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Metronomic scheduling: the future of chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Fas and the art of lymphocyte maintenance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Overview of interleukin-2 as an immunotherapeutic agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 September 2017

Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

30 May 2018

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

30 May 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

30 May 2018

Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2639763

28 November 2018

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose IL-2 reduces lymphocyte apoptosis and increases naive CD4 cells in HIV-1 patients treated with HAART

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results

1 reference

https://pubmed.ncbi.nlm.nih.gov/18698048

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-07-5162

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24655036&oldid=1755910940"